首页> 外文会议>Vaccine technology VI >FAST-TRACK LENTIVIRAL VECTOR UPSTREAM PROCESS DEVELOPMENT: LEVERAGING HIGH- THROUGHPUT PROCESS MONITORING, SINGLE-USE BIOREACTOR SCALABILITY
【24h】

FAST-TRACK LENTIVIRAL VECTOR UPSTREAM PROCESS DEVELOPMENT: LEVERAGING HIGH- THROUGHPUT PROCESS MONITORING, SINGLE-USE BIOREACTOR SCALABILITY

机译:快速痕迹病毒载体的上游工艺开发:利用高通量的过程监控,一次性生物反应器可扩展性

获取原文
获取原文并翻译 | 示例

摘要

The design and applications of recombinant viral vector have significantly increased over the past years for various therapeutic areas such as gene therapy, cell therapy and vaccines. To respond to this growing demand, viral vector production processes should demonstrate robustness and scalability. Thus a high-throughput development method has been implemented to allow fast-track process optimization and scale-up of non-replicative lentiviral vector production by transient transfection. A state-of-the-art process development strategy was put in place to develop robust and highly-productive lentiviral vector production platforms by transient transfection of cell suspension in serum-free conditions. Labscale representative models are developed allowing parallel large number of experiments. Designs of experiments are applied to identify interaction between identified or selected optimized parameters. Disposable solutions are implemented all along the process to decrease development timelines and provide flexibility for panel vectors manufacturing. High-throughput process monitoring tests were also developed to support associated analytical needs. Comparative analysis of results observed within different scales models are presented and discussed, demonstrating good scalability from 15-mL micro-bioreactor up to 200L production scale.
机译:在过去的几年中,重组病毒载体的设计和应用在诸如基因治疗,细胞治疗和疫苗等各种治疗领域已大大增加。为了满足这种不断增长的需求,病毒载体生产过程应表现出鲁棒性和可扩展性。因此,已经实现了一种高通量开发方法,以允许通过瞬时转染实现快速流程优化和按比例放大非复制性慢病毒载体的生产。通过在无血清条件下瞬时转染细胞悬浮液,制定了最新的工艺开发策略来开发强大而高效的慢病毒载体生产平台。开发了Labscale代表性模型,可以并行进行大量实验。应用实验设计来识别已识别或选定的优化参数之间的相互作用。在整个过程中都采用了一次性解决方案,以减少开发时间并为面板矢量制造提供灵活性。还开发了高通量过程监控测试来支持相关的分析需求。提出并讨论了在不同规模模型中观察到的结果的比较分析,证明了从15 mL微型生物反应器到200L生产规模的良好可扩展性。

著录项

  • 来源
    《Vaccine technology VI》|2016年|19-19|共1页
  • 会议地点 Albufeira(PT)
  • 作者

    Nicolas Seve;

  • 作者单位

    BioProcessing Research Development - Upstream, Sanofi Pasteur, Marcy I'Etoile, France;

  • 会议组织
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号